Roche invests 100 million Swiss francs in new laboratory building
Basel, 26 April 2012
Inauguration of modern Quality Control and Quality Assurance laboratory building at Kaiseraugst
Today Roche opened a new laboratory building for Quality Control and Quality Assurance at its site in Kaiseraugst. The building will be used to test the medicines produced and packaged for worldwide distribution at Roche in Basel and Kaiseraugst.
“Roche is constantly working to ensure that our medicines reach the highest possible standards of quality.” said Pascal Soriot, COO of Roche Pharmaceuticals. “This new building is designed to enhance our ability to meet current and future quality control requirements.”
“Bringing these activities together in one location enables us to organise our operations more efficiently,” explained Matthias M. Baltisberger, Roche Basel Site Head. “The very good operating environment and the availability of highly qualified employees here in north-west Switzerland have played a major part in Kaiseraugst’s development into a centre of excellence for manufacturing, logistics and distribution within the Roche Group.”
With its energy requirements met largely from environmental energy sources, the building complies with stringent energy standards that exceed statutory requirements.
About Quality Control and Quality Assurance
Quality Control and Quality Assurance are an essential part of pharmaceutical manufacturing. They are responsible for checking incoming materials that are used to manufacture chemical, pharmaceutical and biotechnological medicines and for checking the final products before they leave the company. Dosage forms such as tablets, capsules and injection solutions in ampoules and prefilled syringes are tested to make sure that they are safe to use.
About the Quality Control and Quality Assurance laboratory building
The new building echoes the architectural style defined by Otto Salvisberg and Roland Rohn for Roche and continues long-standing development practices at the site.
High-quality architecture in the Bauhaus tradition has been the hallmark of Roche’s buildings since the early 20th century.
The functional building design creates maximum flexibility, facilitating rapid, simple adaptation to future requirements. All laboratory buildings have open ceilings so that the spaces within them can be reconfigured at any time.
Around 220 people will work in the new building.
About the Roche logistics centre in Kaiseraugst
Roche completed one of the most up-to-date pharmaceutical packaging and logistics centres in Europe in Kaiseraugst in 1995. The existing production facilities and the logistics centre currently supply medicines to over 130 countries. The site is being expanded in response to growing global demand for Roche biopharmaceuticals such as Actemra, Avastin, Herceptin, MabThera and Pegasys, which have to be stored, packed for shipment and distributed under refrigerated conditions. This will enable Roche to benefit in full from synergies with the existing infrastructure while guaranteeing an integrated supply chain. The Kaiseraugst facility plays a central role within the Roche Group.
The Kaiseraugst site was acquired in the early 1970s. In recent years Roche has invested a total of roughly 400 million Swiss francs in the construction of a sterile manufacturing facility, the new Quality Control and Quality Assurance laboratory building and the expanded logistics centre.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com
All trademarks used or mentioned are protected by law.